IDEAYA and Roche launch IDE892 combo study in PDAC
IDEAYA Biosciences reported a new clinical collaboration with Roche to study IDEAYA’s investigational PRMT5 inhibitor IDE892 with Roche’s pan-RAS inhibitor RG6505 in patients with MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
IDEAYA Biosciences reported a new clinical collaboration with Roche to study IDEAYA’s investigational PRMT5 inhibitor IDE892 with Roche’s pan-RAS inhibitor RG6505 in patients with MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma. IDEAYA will sponsor the trial and Roche will provide RG6505, with both companies retaining commercial rights to their respective drugs.
IDE892 is already in a Phase 1 dose-escalation trial in MTAP-deleted solid tumors, and IDEAYA plans Phase 1 combination cohorts in pancreatic cancer with RG6505 and in other tumors with its MAT2A inhibitor IDE397. The collaboration may also expand to a triplet regimen of IDE892, RG6505 and IDE397 under joint governance between the companies.
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
MTAP deletion prevalence in PDAC: up to 40%
IDE397 development stage: Phase 2
IDE892 development stage: Phase 1
3 metrics
MTAP deletion prevalence in PDAC
up to 40%
Estimated frequency of MTAP deletions in pancreatic ductal adenocarcinoma
IDE397 development stage
Phase 2
MAT2A inhibitor used in planned combination and triplet regimens
IDE892 development stage
Phase 1
Dose escalation trial in MTAP-deleted solid tumors
Key Terms
PRMT5 inhibitor, pan-RAS inhibitor, MTAP deletion, pancreatic ductal adenocarcinoma, +2 more
6 terms
PRMT5 inhibitor medical
"IDE892, its investigational, potential best-in-class PRMT5 inhibitor"
A PRMT5 inhibitor is a drug that blocks the action of the enzyme PRMT5, which controls how some genes are turned on or off by tagging proteins inside cells. For investors, these drugs matter because they can slow or stop the growth of certain cancers and other diseases by reprogramming cell behavior, acting like a dimmer switch for disease-related genes; clinical trial results and approval decisions drive value and risk.
pan-RAS inhibitor medical
"in combination with Roche’s RG6505, a pan-RAS inhibitor"
A pan-RAS inhibitor is a drug designed to block activity of the RAS family of proteins (such as KRAS, NRAS and HRAS) that often drive uncontrolled cell growth in cancers. For investors, it matters because a single medicine that works across multiple RAS types can address a larger group of patients and reduce the risk that a tumor will bypass the drug, much like cutting power to several faulty switches instead of just one.
MTAP deletion medical
"in patients with pancreatic ductal adenocarcinoma that carry an MTAP deletion"
mtap deletion is the loss of the MTAP gene from a cell’s DNA, which can happen in some cancers. For investors, it matters because that genetic gap often creates a predictable weakness drugs can target, making affected tumors both a potential market for specialized therapies and a marker used by companies to select patients for trials; think of it as a missing bolt that lets a tailored tool work more effectively.
pancreatic ductal adenocarcinoma medical
"in patients with pancreatic ductal adenocarcinoma (“PDAC”) that carry an MTAP deletion"
A fast-growing cancer that starts in the cells lining the pancreas’ small ducts; it is the most common and aggressive form of pancreatic cancer. It matters to investors because its severity and limited treatment options drive high unmet medical need, large potential markets for effective drugs or diagnostics, and strong sensitivity of company valuations to clinical trial results, regulatory approvals, or changes in treatment guidelines—similar to how fixing a main leak can prevent major damage in a building.
MAT2A inhibitor medical
"with IDE397, the Company’s proprietary MAT2A inhibitor"
forward-looking statements regulatory
"Certain statements contained herein are forward-looking statements"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What clinical collaboration did IDEAYA Biosciences (IDYA) announce with Roche?
IDEAYA Biosciences announced a clinical collaboration with Roche to evaluate IDEAYA’s PRMT5 inhibitor IDE892 combined with Roche’s pan-RAS inhibitor RG6505 in MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma, with IDEAYA sponsoring the study and Roche supplying RG6505.
Which cancer types are targeted in the IDEAYA (IDYA) and Roche IDE892 collaboration?
The collaboration focuses on MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma. IDEAYA also plans Phase 1 combination cohorts using IDE892 in pancreatic cancer with RG6505 and in non-small cell lung cancer plus other solid tumors together with its MAT2A inhibitor IDE397.
What is IDEAYA’s IDE892 and how is it being developed?
IDE892 is an investigational PRMT5 inhibitor designed as a potential best-in-class therapy. It has shown robust monotherapy regressions in MTAP-deleted preclinical models and is being evaluated in a Phase 1 dose escalation trial in MTAP-deleted solid tumors, including planned combination cohorts.
How common are MTAP deletions in pancreatic ductal adenocarcinoma according to IDEAYA (IDYA)?
IDEAYA states that MTAP deletion is estimated to occur in up to 40% of pancreatic ductal adenocarcinoma cases. The company also notes that almost all MTAP-deleted pancreatic tumors harbor co-occurring RAS mutations, supporting the rationale for combining PRMT5 and pan-RAS inhibitors.
Who retains commercial rights in the IDEAYA (IDYA) and Roche IDE892 clinical collaboration?
Under the collaboration, IDEAYA and Roche each retain all commercial rights to their respective compounds, both as monotherapies and in combination regimens. A joint governance process between the companies will oversee the clinical combination study and any potential triplet regimen decisions.
Could the IDEAYA (IDYA) and Roche collaboration include IDE397 in a triplet regimen?
Yes. The collaboration allows for potential evaluation of a triplet combination of IDE892, RG6505 and IDEAYA’s Phase 2 MAT2A inhibitor IDE397. Any triplet study would require joint approval from both companies and would build on their MTAP-deletion targeting strategy.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates